- Record: found
- Abstract: not found
- Article: not found
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E Pratley ,
Vanita R Aroda ,
Ildiko Lingvay ,
Jörg Lüdemann ,
Camilla Andreassen ,
Andrea Navarria ,
Adie Viljoen
April 2018
April 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Despite common mechanisms of actions, glucagon-like peptide-1 receptor agonists differ
in structure, pharmacokinetic profile, and clinical effects. This head-to-head trial
compared semaglutide with dulaglutide in patients with inadequately controlled type
2 diabetes.